Affordable Access

deepdyve-link
Publisher Website

Acute Neurofunctional Effects of Escitalopram in Pediatric Anxiety: A Double-Blind, Placebo-Controlled Trial.

Authors
  • Lu, Lu1
  • Mills, Jeffrey A2
  • Li, Hailong3
  • Schroeder, Heidi K2
  • Mossman, Sarah A2
  • Varney, Sara T2
  • Cecil, Kim M4
  • Huang, Xiaoqi3
  • Gong, Qiyong5
  • Ramsey, Laura B2
  • DelBello, Melissa P2
  • Sweeney, John A1
  • Strawn, Jeffrey R2
  • 1 West China Hospital of Sichuan University, Chengdu, China; University of Cincinnati, Ohio. , (China)
  • 2 University of Cincinnati, Ohio.
  • 3 West China Hospital of Sichuan University, Chengdu, China. , (China)
  • 4 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
  • 5 West China Hospital of Sichuan University, Chengdu, China. Electronic address: [email protected] , (China)
Type
Published Article
Journal
Journal of the American Academy of Child and Adolescent Psychiatry
Publication Date
Oct 01, 2021
Volume
60
Issue
10
Pages
1309–1318
Identifiers
DOI: 10.1016/j.jaac.2020.11.023
PMID: 33548492
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Amygdala-ventrolateral prefrontal cortex (VLPFC) circuitry is disrupted in pediatric anxiety disorders, yet how selective serotonin reuptake inhibitors (SSRIs) affect this circuitry is unknown. We examined the impact of the SSRI escitalopram on functional connectivity (FC) within this circuit, and whether early FC changes predicted treatment response in adolescents with generalized anxiety disorder (GAD). Resting-state functional magnetic resonance (MR) images were acquired before and after 2 weeks of treatment in 41 adolescents with GAD (12-17 years of age) who received double-blind escitalopram or placebo for 8 weeks. Change in amygdala-based whole-brain FC and anxiety severity were analyzed. Controlling for age, sex, and pretreatment anxiety, escitalopram increased amygdala-VLPFC connectivity compared to placebo (F = 17.79, p = .002 FWE-corrected). This early FC change predicted 76.7% of the variability in improvement trajectory in patients who received escitalopram (p < .001) but not placebo (p = .169); the predictive power of early amygdala-VLPFC FC change significantly differed between placebo and escitalopram (p = .013). Furthermore, this FC change predicted improvement better than baseline FC or clinical/demographic characteristics. Exploratory analyses of amygdala subfields' FC revealed connectivity of left basolateral amygdala (BLA) -VLPFC (F = 19.64, p < .001 FWE-corrected) and superficial amygdala-posterior cingulate cortex (F = 22.92, p = .001 FWE-corrected) were also increased by escitalopram, but only BLA-VLPFC FC predicted improvement in anxiety over 8 weeks of treatment. In adolescents with GAD, escitalopram increased amygdala-prefrontal connectivity within the first 2 weeks of treatment, and the magnitude of this change predicted subsequent clinical improvement. Early normalization of amygdala-VLPFC circuitry might represent a useful tool for identifying future treatment responders as well as a promising biomarker for drug development. Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety; https://www.clinicaltrials.gov/; NCT02818751. Copyright © 2021 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.

Report this publication

Statistics

Seen <100 times